HLB Panagene KRX:046210KOSDAQ
HLB파나진 · Korean news coverage and regulatory filings, organized.
In Q3 2026, HLB Panagene reported revenue of ₩3.5bn, down 2.6% year on year, and an operating loss of ₩141m. HLB Panagene (HLB파나진) appeared in 16 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Nov 11 with 16 articles. The most common catalyst was clinical & approvals (6).
Filing signals 4 quarters of losses Screener
HLB Panagene today: up or down?
No sign-up, one tap a day. These numbers show what visitors think and are not investment advice.
Upcoming dates as filed
- Nov 16 Quarterly report filing deadlinetoday · period ending Sep 2026
Dates HLB Panagene stated in its DART filings. A conversion period opening does not mean new shares appear that day; bondholders must request conversion.
HLB Panagene quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q3 2026 | ₩3.5bn | -2.6% | −₩141m margin −4.0% | −₩989m |
| Q2 2026 | ₩3.7bn | +1.9% | −₩158m margin −4.3% | ₩1.6bn |
| Q1 2026 | ₩3.1bn | -11.6% | −₩749m margin −23.9% | −₩1.1bn |
| Q4 2025 derived | ₩4.2bn | +21.9% | −₩1.7bn margin −39.6% | −₩3.6bn |
| Q3 2025 | ₩3.6bn | -5.6% | −₩829m margin −22.8% | −₩164m |
| Q2 2025 | ₩3.6bn | +47.7% | −₩200m margin −5.5% | ₩1.2bn |
| Q1 2025 | ₩3.5bn | +3.9% | −₩733m margin −20.7% | −₩584m |
| Q4 2024 derived | ₩3.5bn | +30.8% | −₩270m margin −7.8% | ₩1.1bn |
HLB Panagene ranks #1511 of 2,345 Korean listed companies by Q3 2026 operating profit. Q3 2026 Korean earnings rankings →
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
HLB Panagene top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest HLB Panagene news Korean headlines
-
MajorHLB Panazine acquires HPV molecular diagnostic product approval in Mexico
2 more on this story · 2 outlets
-
HLB Panajin receives HPV diagnostic product approval in Mexico
8 more on this story · 8 outlets
- HLB Panajin receives HPV diagnostic product approval in Mexico…accelerating Latin America strategy더바이오 · Nov 11 09:06
- HLB Panajin receives HPV diagnostic product Class 2 medical device approval in Mexico…beginning full-scale local operations팍스경제TV · Nov 11 09:07
- HLB Panagin targets 1.8 trillion won market, gains Mexico approval for human papillomavirus diagnostic productCatchNews · Nov 11 09:30
- HLB Panagin gains Mexico approval for human papillomavirus diagnostic product한국금융신문 · Nov 11 09:43
- HLB Panadyne obtains HPV diagnostic product approval in Mexico…accelerates Latin America strategy아시아타임즈 · Nov 11 09:45
- HLB Panazine gains Mexico approval for HPV diagnostic product, accelerates Central and South America market expansionEBN · Nov 11 10:50
- BioS HLB Panagen HPV molecular diagnostics Mexico medical device approved이투데이 · Nov 11 11:09
- HLB Panajin wins HPV diagnostic product approval in Mexico, accelerating Central and South America push디지털타임스 · Nov 11 13:42
-
HLB Panagene reveals major AOC platform technology at international conference
2 more on this story · 2 outlets
- HLB Panagene unveils major AOC platform technology overseas아이뉴스24 · Oct 14 15:01
- HLB Panagene reveals AOC platform core technology at Denver conference뉴스핌 · Oct 14 15:11
-
HLB Panagene discloses PNA design technology…reinforces basis for AOC therapeutic development
1 more on this story · 1 outlets
-
HLB Panagene presents PNA optimization research at US OTS…applied to AOC therapeutic development
1 more on this story · 1 outlets
- HLB Panasgin presents PNA preclinical research at OTS메디포뉴스 · Oct 14 19:37
-
HLB Panasgin presents PNA chemical modification technology at international conference
2 more on this story · 2 outlets
- HLB Panasgin presents PNA chemical modification research results at U.S. conference이투데이 · Sep 29 10:48
- HLB Panasgin presents PNA chemical modification research results at OTS 2026파이낸셜뉴스 · Sep 29 11:47
-
HLB Panasgin discloses PNA chemical modification technology based on AOC development at global conference
3 more on this story · 3 outlets
- HLB Panasgin reveals PNA therapeutic technology based on AOC development뉴스1 · Sep 29 14:07
- HLB Panasgin presents AOC-based PNA research at global conference핀포인트뉴스 · Sep 29 14:38
- HLB Panasgin discloses PNA variant technology; applies to AOC development메디파나뉴스 · Sep 29 15:29
-
HLB Panasgin terminates immunodiagnostics development business; concentrates on new AOC and spatial protein ventures
5 more on this story · 5 outlets
- HLB Panasgin restructures business; focuses on new AOC and spatial protein businesses더바이오 · Sep 18 16:35
- HLB Panasgin reorganizes immunodiagnostics business; pivots to new AOC and spatial protein ventures이투데이 · Sep 18 16:45
- HLB Panasgin restructures business; concentrates on AOC and spatial protein new businesses머니투데이 · Sep 18 16:47
- HLB Panasgin reorganizes immunodiagnostics business; focuses on AOC and spatial proteinPRESS9 · Sep 18 16:51
- HLB Panasgin reorganizes immunodiagnostics business; focuses on AOC and spatial protein뉴스1 · Sep 18 17:15